MedTrace Logo

Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

NCT02724358 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2016-03-31

No results posted yet for this study

Summary

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Conditions

Interventions

PROCEDURE

TACE

iodized oil (5ml) + Pirarubicin (20mg)

DRUG

Rg3

20mg, BID, maintained though Month 12.

OTHER

TACE + Rg3

PROCEDURE

protective therapy

standard liver protective therapy

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02724358 on ClinicalTrials.gov